We also demonstrated that an FDA-approved D2R agonist, cabergoline, reduced NSCLC growth in mice and reported that a subset of NSCLC patients have increased endothelial D2R expression, suggesting potential precision oncology treatment strategies are possible [60]. The gene discussed is DRD2; the disease is non-small cell lung carcinoma.